Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Gene Review:

MMP13 - matrix metallopeptidase 13 (collagenase 3)

Canis lupus familiaris

Pelletier, J.P. et al., Rajamäki, M.M. et al., Kuroki, K. et al., Pelletier, J.P. et al., Campbell, S.E. et al., et al.

Rajamäki, Järvinen, Sorsa, Maisi,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MMP13

The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K [1].
We studied and characterized the collagenolytic matrix metalloproteinases (MMP-8 and MMP-13) in the pathogenesis of canine pulmonary eosinophilia (PE) [2].
The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases [3].

High impact information on MMP13

Neither secreted collagenases (MMP-1 and MMP-13), gelatinases (gelatinase A or B), stromelysins (MMP-3 and MMP-11), or matrilysin (MMP-7) affected SF/HGF-induced responses [4].
Treatment with licofelone decreased, in a dose-dependent manner, the OA bone morphological changes at the same time it reduced the level of MMP-13 in bone cells and the number of cathepsin K and MMP-13 positive osteoclasts [1].
The canine MMP-13 promoter fragment was sufficient to drive basal expression of a luciferase reporter gene in both Madin Darby canine kidney cells (MDCK) and primary rat cardiocytes [5].
Myocardial MMP-9 and MMP-13 levels by immunoblot increased with chronic pacing relative to controls (130 +/- 10% and 118 +/- 6%, P < 0.05) and was normalized by TNF block [6].
MMP-13 gene expression as determined by real-time reverse transcription polymerase chain reaction was elevated in OC samples and cartilage explants cultured without mechanical stimuli (0 MPa groups) compared to normal cartilage (day 0 controls) [7].

Anatomical context of MMP13

These changes were associated with an increased level of MMP-13 synthesis by bone cells and an increase in the osteoclast population that stained strongly positive for cathepsin K and MMP-13 [1].
Major immunoreactivity for MMP-8 was observed in macrophages and epithelial cells, and major immunoreactivity for MMP-13 was observed in macrophages [2].

Analytical, diagnostic and therapeutic context of MMP13

Quantitative RT-PCR showed that PD-0200347 significantly reduced the expression of MMP-13, a key mediator in OA [8].
Western immunoblotting identified the presence of MMP-8 and MMP-13 immunoreactivities, of which the latter was converted to active form [2].

References

The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Pelletier, J.P., Boileau, C., Brunet, J., Boily, M., Lajeunesse, D., Reboul, P., Laufer, S., Martel-Pelletier, J. Bone (2004) [Pubmed]
Collagenolytic activity in bronchoalveolar lavage fluid in canine pulmonary eosinophilia. Rajamäki, M.M., Järvinen, A.K., Sorsa, T., Maisi, P. J. Vet. Intern. Med. (2002) [Pubmed]
The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases. Pelletier, J.P., Boileau, C., Boily, M., Brunet, J., Mineau, F., Geng, C., Reboul, P., Laufer, S., Lajeunesse, D., Martel-Pelletier, J. Arthritis Res. Ther. (2005) [Pubmed]
Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. Hotary, K., Allen, E., Punturieri, A., Yana, I., Weiss, S.J. J. Cell Biol. (2000) [Pubmed]
The cloning and functional analysis of canine matrix metalloproteinase-13 gene promoter. Campbell, S.E., Sood, A., Argyle, D.J., Nasir, L., Argyle, S.A., Bennett, D. Gene (2002) [Pubmed]
TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Bradham, W.S., Moe, G., Wendt, K.A., Scott, A.A., Konig, A., Romanova, M., Naik, G., Spinale, F.G. Am. J. Physiol. Heart Circ. Physiol. (2002) [Pubmed]
Characterizing osteochondrosis in the dog: potential roles for matrix metalloproteinases and mechanical load in pathogenesis and disease progression. Kuroki, K., Cook, J.L., Stoker, A.M., Turnquist, S.E., Kreeger, J.M., Tomlinson, J.L. Osteoarthr. Cartil. (2005) [Pubmed]
Oral treatment with PD-0200347, an alpha2delta ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Boileau, C., Martel-Pelletier, J., Brunet, J., Tardif, G., Schrier, D., Flory, C., El-Kattan, A., Boily, M., Pelletier, J.P. Arthritis Rheum. (2005) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use

[search][advanced]